BioNTech Completes Acquisition of CureVac, Strengthening Its Position in the mRNA Field
TL;DR
BioNTech has acquired CureVac, gaining 86.75% of shares, with full completion expected by January 2026. This deal enhances BioNTech's mRNA capabilities and supports its oncology strategy, while CureVac continues its operations.
Tags
BioNTech has acquired CureVac N.V. in a deal that complements its capabilities in mRNA design, delivery formulations, and manufacturing. Approximately 86.75% of CureVac shares were tendered, with BioNTech expecting to complete the compulsory acquisition of the remaining shares in January 2026. CureVac will continue to operate under its existing processes, while BioNTech will analyze future organizational and portfolio setup. The acquisition strengthens BioNTech's position in the mRNA field and supports its oncology strategy.
